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SUMMARY
Glucose-6-phosphate dehydrogenase is the first enzyme in the pentose phosphate pathway and the main intracellular source
of reduced nicotidamineadenine nucleotidephosphate (NADPH), involved in diverse physiological processes such as antioxidant
defense, (for instance in the erythrocyte) endothelial growth modulation, erithropoyesis, vascularization and phagocitosis. G6PDH
deficiency is the most common X-chromosome-linked enzymopathy in human beings. Although it is present in any type cell, its
absolute deficiency is incompatible with life. According to WHO, 400 million people are affected by G6PD deficiency in the world
but in Colombia, the severe form prevalence is about 3% to 7%. There  are no data related to slight and moderate alterations, that
also have clinical effects. This paper reviews some G6PD biomolecular aspects, its classification according to activity and
electrophoretic mobility, as well as  some main clinical aspects related to its activity alteration.
Keywords: Erythrocyte; Physiology; Genetics; Epidemiology; Glucose-6-phosphate dehydrogenase deficiency;
Congenital hemolytic anemia.
Glucosa-6-fosfato deshidrogenasa (G6PD). Respuesta de los hematíes y otras células humanas a la disminución en su
actividad
RESUMEN
La glucosa-6-fosfato deshidrogenasa (G6PD) es la primera enzima de la vía pentosa fosfato y la principal fuente intracelular de
nicotidamina adenina dinucleótido fosfato reducido (NADPH), compuesto  comprometido en diversos procesos fisiológicos,  por
ejemplo defensa antioxidante (sobre todo células como los eritrocitos), modulación del crecimiento endotelial, eritropoyesis,
vascularización y fagocitosis. La deficiencia de G6PD es la enzimopatía ligada al cromosoma X más común en el ser humano. Si bien
se puede presentar en cualquier tipo de célula, su carencia absoluta es incompatible con la vida. Según la OMS, en el mundo  hay
más de 400 millones de personas afectadas por la deficiencia de la enzima, y para  Colombia calculan una prevalencia de la deficiencia
severa entre 3% y 7%, pero no se conocen los datos relativos a las alteraciones leves y moderadas, que también tienen efectos
clínicos. El presente artículo revisa los aspectos biomoleculares más  importantes de la enzima, su clasificación de acuerdo con la
actividad y la movilidad electroforética,  y también se mencionan algunos aspectos clínicos relacionados con la alteración de su
actividad.
Palabras clave: Ultraestructura; Fisiología; Genética; Epidemiología; Deficiencia de glucosafosfato deshidrogenasa;
Eritrocitos; Anemia hemolítica congénita.
All living organisms, be yeasts or protozoa, plants or
animals express the glucose-6-phosphate dehydrogenase
enzyme (G6PD)1.
Though G6PD is found in the cytoplasm of all mammals
cells, its deficiency is more evident in the red blood cells
probably because these cells live without nucleus for a
long time and because they contain proteases that degrade
the mutant enzyme in major degree than other proteases
in other tissues1.
Since the erythrocyte is a cell that transports oxygen by
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excellence, its mechanisms of defense against the oxidative
stress make part of the maintenance of its circulating
activity. These defense mechanisms depend in a great
part on the metabolic supply of the reduced form of NADP
(NADPH + H+). Due to the particular metabolic
characteristics of these cells, only the two first reactions
of the pentose via (also called hexose monophosphate)
have the capacity to generate NADPH + H. These are
first the conversion of the glucose-6-phosphate into phospho
gluconic acid-6 and second the conversion of these
intermediate one into ribulose-5-phosphate with CO2
detachment. These two reactions are sequential and in
both the NADP is reduced. While the first one is catalyzed
by the G6PD enzyme, the second one it is by the 6-
phosphogluconate dehydrogenase.
Through the production of NADPH the erythrocytes
reduce the oxidative glutathione to reduced glutathione
which process is catalyzed by the glutathione reductase
enzyme which is a flavoprotein with FAD (flavin adenin
dinucleotic). At the same time the reduced glutathione
retires the H2O2, from the erythrocyte in a reaction
catalyzed by the peroxidase glutathione. This reaction is
important because the H2O2 might reduce the life
expectancy of the erythrocytes for the increase in the
speed of hemoglobin oxidation to metahemoglobin2 (Figu-
re 1).
G6PD deficiency produces irreversible oxidative
damage and cell death3. The average life of 60 days of the
enzyme reflects stepwise the age of the red blood cells.
This way to major age the activity of some enzymes
decreases since the erythrocytes are unable to synthesize
new protein molecules. For this reason, the reticulocytes
have an enzymatic activity five times major than that of the
senescent4 red blood cells and they must be separated
before determining the enzyme activity.
Structure. The Glucose-6-phosphate dehydrogenase
(E.C. 1.1.1.49; D-glucose-6-phosphate: NADP oxido-
reductase)5 enzyme is present in all cells. In the erythrocytes
it is found in its dimeric and tetrameric forms. The
monomer has a molecular weight of 59,256 daltons and
counts with 515 amino acids. The catalytic activity is only
initiated when an association is established, in balance
status, between the dimeric and tetrameric 6 forms.
Such an association requires the NADP presence,
strongly tied by the enzyme7,8 which makes that NADP
performs a dual role not only as structural component but
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as a coenzyme9-11. In 1967, Luzzatto12 postulated at least
two sites of union of the NADP to the enzyme, with a
condition of transition from low to high affinity when
NADP’s concentration increases, which means that there
exist two possible forms of the enzyme, according to its
affinity by the NADP. These conditions might change in
case of appearance of a competitive inhibitor of the
NADPH. The low constant of dissociation for the NADPH
suggests that the reaction can be a very efficient controller,
acting as a feedback, which would regulate the enzymatic
activity. These facts allowed to establish that the relation
of NADP/NADPH concentration is a regulatory
mechanism of the activity of the G6PD and therefore of
the hexose monophosphate (HMP) in the red blood cells.
Function. The importance of the G6PD is found in the
transcendence of the cellular processes in which it takes
part, such as:
NADPH genesis effected from the first two steps of
the hexose monophosphate. The NADPH takes part in the
biosynthesis that reduces cholesterol and oil acids and also
in the synthesis of the nitric oxide (NO). On the other hand
it is needed for the activity of the metahemoglobin reductase
and for the maintenance of the reduced level of glutathione
(GSH). NADPH and GSH are responsible for the potential
redox effective to protect from the oxidative stress the
groups of sulfhydryl of the cellular membrane, as well as
the enzymes and the hemoglobin that compromises
erythrocyte survival3.
Other functions that show the transcendence of this
enzyme in the cell life are the following:
1. Regulation of the activity of the KU protein implied in
repairing the DNA after the damage that radiations
cause. The intervention of the G6PD is effected
through the pentose cycle and consists of facilitating
the union of KU - with reduced cysteine residues- to
the DNA in repairing process13.
2. Early development of the embryo. When there is a
severe G6PD deficiency in the extra-embryonic tissues,
the placenta development stops and the embryo dies14.
3. Survival of the fetus during the transition of the fetal
hemoglobin to the adult form. Here the G6PD prevents
the oxidative damage due to the generation of species
reactive to oxygen from the adult hemoglobin14,15.
4. Phagocytosis in white cells. The severe deficiency of
this enzyme results in a reduction of the NADPH
generation, which results in a decrease in the production
of hydrogen peroxide (H2O2) and therefore the
neutrophil microbicide activity is affected and likewise
its inflammatory response16. Though the clinical
characteristics of the severe deficiency are similar to
those of the granulomatosa chronic disease (EGC), its
appearance happens, unlike the latter, during more
advanced stages of life17,18. The EGC constitutes a
fundamental model to investigate the composition and
the activation of the microbicide system of the phago-
cyte cells, especially of the neutrophil ones. This entity
is caused by a deep defect in the respiratory explosion
that accompanies the phagocytosis of all myeloid cells
(neutrophil, eosinophile, monocyte, macrophage). The
respiratory explosion generates the catalytic conversion
of the molecular oxygen in the super oxide anion that
leads to the hydrogen peroxide  formation, the
hypochlorous acid and the hydroxile radicals. These
derivates from the oxygen play an important role in the
microbicide reaction against bacteria and fungi19,20.
5. Modulation of the vascular endothelial factor growth
that regulates the angiogenesis. NADPH is used as a
cofactor of the endothelial nitric oxide sintetase (eNOS).
Therefore the nitric oxide required for the modulation
of the growth and for the endothelial migration during
the vascular growth is maintained in an adequate
level17.
6. Most of the genes able to reduce the risk against
certain infections as the malaria are expressed in the
red blood cell, which is considered like a genetic and/
or evolutionary mechanism of defense, as in the case
of the genes that express the G6PD21.
Deficiency. The G6PD deficiency still prevails as the
most common of all the inherited enzymatic defects22,23
and it is clinically significant not only in the hematological
field but also in the human biology24 and it is characterized
by a large biochemical and genetic heterogeneity. The
deficiency of G6PD has been the prototype within the
hemolytic anemias due to an enzymopathy as a primary
abnormality of the erythrocyte. Likewise it is an example
of hemolytic anemia due to an interaction between extra
cellular and intracellular causes, since hemolysis in most
cases is triggered by exogen agents25.
Hemolysis of deficient red blood cells occurs as a
consequence of the increase in the susceptibility to the
oxidative damage due to the incapacity of cells to reduce
the NADP to NADPH in a normal way. In presence of
oxidant agents the NADPH production through the HMP
is stimulated multiple times so that the NADPH and GSH
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levels maintain stable. These events are due to the over-
expression of G6PD26. The exact mechanism involved in
the increase of the sensibility to the oxidative damage,
facilitator of hemolysis, is not clear yet. However, there
exists a significant volume of information on the favism,
which is higher than the available one about the different
medicines that might produce it. Faba beans contain
compounds such as divicine and isouramil that produce
irreversible GSH oxidation as well as in other groups of
proteins united by SH groups. This favors not only an
electrolytic unbalance in the red blood cells, but also the
union by the intercrossing of membranes and microvesi-
culization, events accompanied by an increase in the
calcium concentration in erythrocyte27.
The G6PD deficiency is produced by different genetic
mechanisms such as deletions, precise mutations and
substitutions that affect the transcription, process or primary
enzyme structure, which functionally results in a decrease
of the enzymatic activity or loss of affinity by the substrate.
There are other factors that influence the activity of the
enzyme. Thus, in a study whose objective was to determi-
ne the possible relation between the activity of the G6PD
enzyme and the hypoxia, it was found that the hypoxia
favored a decrease in its activity27,28.
Variants. The true deficiency of G6PD was identified
initially in the middle of the last century, in black race North
americans during the investigations carried out over the
hemolytic effect of the primaquine19. At the present time
such medicine continues being a causal agent of the
deficiency in Iraqi soldiers with malaria 29.
From mid of the last century, it was accepted that the
primary metabolic defect in individuals susceptible to the
hemolysis secondary to medicines or to the faba bean
consumption (Vicia faba), corresponds to a low activity of
the G6PD in erythrocytes30. Although the association
between the deficiency of G6PD and the non-immune
hemolytic and the non-spherocytic anemia 22 is clearly
defined, also it is evident its correlation with the hemolysis
due to medicines, food and to other events such as
infection processes, situation outlined by Vulliamy et al.31
as the most important cause of hemolysis. Towards 1958,
Gross et al.30, on one hand and Szeinberg et al.22 on the
other one, determined that the enzymatic deficiency had a
hereditary base and suggested that it was bound to sex.
The biochemical characterization allowed identifying not
less than 442 variants of the deficiency of the enzyme.
About 229 of them were described by methods used by the
expert group of the World Health Organization (WHO).
On the other hand 60 mutations or their combinations were
documented, all of precise nature taking into account that
the total deficiency is incompatible with life23.
According to its activity level the enzyme variants were
classified in five types23, such as:
Class 1: Deficiency of the enzyme with chronic non-
spherlocytic-hemolytic anemia (CNSHA).
Class 2: Severe Enzymatic deficiency (less than 10%,
for example the mediterranean form).
Class 3: Moderate enzymatic deficiency (10%-60%,
for example, the African form).
Class 4: Low or absent enzymatic deficiency (60%-
100%).
Class 5: Enzymatic activity above normal rates.
The class 1 variant is a rare and severe one, associated
with chronic non-spherocytic hemolytic anemia. Of sporadic
appearance, their cases are considered unique31. In regions
such as the African and Asian continents and the
Mediterranean river basin there exists a high frequency of
the different variants of the enzymatic deficiency, whereas
in China and Japan the frequency is low23.
In the Mediterranean populations the enzymatic
deficiency is much more severe and frequent than in the
population of North American black race32, where the
defect was identified in the red blood cells.
In contrast, this one was found in several diverse
cellular types, obtained in Italian sensible individuals and of
Jewish race33. With respect to the frequency of the severe
deficiency, the variation between the different populations
is notorious. Thus, among the black race Americans, the
frequency of the gene of the enzymatic deficiency is from
0.10% to 0.11%34 with 15% of enzymatic  activity related
to normal35. As an example of an elevated frequency of
the deficiency, we may mention the Kurd Jews where it
reaches, in its Mediterranean form, an equal value to
0.70%36. The Mediterranean form is a variant whose
frequency of polymorphism has an activity lower than
10%. In it, the mutation appears in the 188 amino acid, with
substitution of phenylalanine (Phe) by serine (Ser)37.
In Saudi Arabia the most frequent variant is the
Mediterranean one, with frequencies that oscillate between
0% and 0.4% in men and 0% and 0.2% in women. It is
possible that the high prevalence in women obeys to a
uniparental dysomia or, to the high existing consanguinity
or to that the chromosome X containing the normal gene
is the one that inactivates itself during the genetic imprints38.
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In Latin America some variants of the enzyme have
been described. In Mexico for example, 18 were identified,
which are also of common appearance in other regions like
the African continent, the south of Europe and the Southeast
Asia 39. Whereas in Mexico the frequency of the deficiency
was between 0.4% and 4.1%, in Cuba it was 4.9% with a
prevalence of the variant A-, and 7% for the A+ variant40.
For countries like Colombia, the frequency calculated by
the WHO for the variants phenotypically associated with
the severe deficiency (Type 2, with lower activity than
10%) is between 3% and 7%23. Nevertheless, in a survey
developed among 103 individuals of masculine sex, donors
of the Blood Donation Point of the Colombian Red Cross
and in appearance healthy, it was found a frequency of
subnormal activity (<60%) of approximately 19.4%. This
research was developed between June and October of
2003, by means of the application of the qualitative technique
of Beutler E (Palomino F. 2003. Universidad Nacional de
Colombia, Perssonal communication).
Another classification is realized by comparing the
electrophoretic mobility of the different variants with the
normal B enzyme, being the variant A- enzyme, present in
individuals of black race with low enzymatic activity,
faster in alkaline pH than the normal enzyme, in contrast,
the variant of the Mediterranean deficient individual’s
moves at a normal speed37. Another frequent variant, A+,
has a normal activity and it is found in about 20% of the
North Americans of black race. This variant is electro-
phoretically faster than the B, fact that is understood
taking into account that the substitution of asp (neutral
amino acid) by asn (acid amino acid) in 126 positions
modifies the enzyme electrical charge, which is reflected
in a faster electrophoretic mobility37.
The variant A- is found in near 11% of the North
American black population. However, its frequency is
greater in the African sub-saharan black population. The
enzymatic activity of this variant corresponds to 5% and
15% of the normal one, this decrease is due to the
presence of two substitutions, not of one as it happens in
the A+ variant. One of these substitutions is similar to the
one that appears in variant A+ and the other one, unique
for this variant, obeys to the change of the val for met in
the 68 position41.
Genetics. The G6PD enzyme is codified by a gene that
is present in the terminal region of the long arm of
chromosome X, (Xq28), less than 2 centi-Morgan to the
gene of factor VIII. In men, the hereditary condition linked
to X determines its hemizygotic character, which means
that there is a single one allele, due to the absence of locus
homologous. There are also homozygotic women in
populations where the frequency of the G6PD deficiency
is high. Hemocygotic women are carriers although they
might develop hemolytic attacks. The G6PD gen has been
mapped in the distal part of the long arm, its length is 18 Kb
and counts with 13 exons42 (Table 1).
The region of the gene to be codified for the protein
includes 12 segments, with an average size between 12
and 236 bp and one intron present in the non-translator
region 5'. In many cellular lines, the greater end 5' of the
G6PD mRNA is located at a distance of 177 bp «upstream»
from the transcription initiation codon43,44. Although the
mutations extend throughout the coding region of the gene,
there exist few (4 of 56) that give origin to the most severe
form of deficiency of the enzyme, this is, the one that is
associated with CNSHA (type 1) in the 160 amino acids
of the N-terminal end. However, there is no one that
causes moderate forms of deficiency (types 2 and 3) in the
48 amino acids of the C-terminal end. Many variants in this
region exhibit abnormal electrophoretic mobilities and are
particularly unstable when the NADP concentration is
low. This is because this region codifies for the domain of
the union to NADP45.
In the A- variant a substitution identical to A+ is
present, although there is a second substitution in the 202
G  --->A nucleotide of exon 4 which results in the change
of val for met, accompanied by the instability of the
enzyme in vivo. Therefore the difference between forms
A and B corresponds to the amino acid that occupies the
126 position, probably as a result of an alternate join or
«splicing» of considerable heterogeneity among the different
Table 1
Molecular characteristics of the G6PD gene
DNA Localization Xq2.8
Gen size (in kilobasis)  18.5
Number of exons 13
Number of introns 12
mRNA Size (in nucleotides)  2269
Proteín Number of amino acids  515
Molecular weight (in daltons) 59,265
Subunits by molecule of
Active enzyme  2 or 4
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cDNAs of the G6PD41.
Clinical manifestations. Almost all the people who
attend with the G6PD deficiency are usually asymptomatic
and the disease is only pronounced when they ingest drugs
or chemicals that trigger the intravascular massive
hemolysis. The clinical expression then results from the
interaction of the molecular properties of each G6PD
variant and from exogenous factors. Different clinical
syndromes associated with the deficiency of this enzyme
have been described and they include:
Hemolysis induced by drugs. Classically, after
ingestion of certain agents like sulfamides, antipyretics,
nitrofurans and antimalarial medicines, like the primaquine
and chloroquine, the patient develops fever, black color
urine, ictericia and anemia. The acute tubular necrosis
might complicate the severe hemolytic episode, mainly in
the underlying diseases of the liver, like hepatitis. The
maintenance of the adequate renal flow of the blood, by
forced alkaline diuresis, might prevent this complication.
In these cases with the committed renal flow of the blood
as evidenced by the low flow of urine, the transfusion is the
ideal in order to eliminate the damaged red cells that block
the microcirculation and can also avoid the renal
complication. In some patients, the disseminated intra-
vascular coagulation (DIC) might complicate the massive
intravascular hemolysis and might need the appropriate
treatment45.
Hemolysis induced by infection. The infection is
perhaps the most common cause in patients with G6PD
deficiency. The mechanism of hemolysis induced by
infections is not well known yet; an explanation may be
that the generation of hydrogen peroxide by the
polymorphonuclear neutrophiles might cause a decrease
in the quantity of reduced glutathione, whose function is to
eliminate, from the red cell, the accumulated metabolites
that oxidate the sulfhydryl groups formed by the oxidative
stress and therefore decreasing the protective capacity of
the cell. On the other hand, the activation of the neutrophiles
takes part directly in the peroxidation of lipids of the
membrane and causes directly the destruction of the
cell46. The severity and clinical consequences are influenced
by many factors that include the simultaneous
administration of oxidating medicine, the previous levels of
hemoglobin, the hepatic function and the age47.
Favism. It is recognized from the antiquity; patients
present a clinical picture similar to the induced by drugs,
that is triggered within the following 24 to 48 hours after
the ingestion of faba beans. It is characterized by the
presence of a picture of acute hemolysis after ingesting
faba beans; however, not all individuals with G6PD
deficiency present hemolysis when ingesting faba beans48.
Favisms symptoms are developed a few hours after the
ingestion. The most common are nausea, vomit, discomfort
and dizziness. After these symptoms there occurs an
acute hemolysis where frequently the recount of
erythrocytes falls below 1.0 x 1012/l. In most red blood cells
Heinz bodies appear. The hemoglobinemia and
hemoglobinuria are present. Symptoms stopped generally
after 2 to 6 days49,50.
Nonspherocytic chronic hemolytic anemia. The
variants of type I, are characterized by this finding, due to
the so severe degree of enzymatic deficiency. The hemolysis
is only partially intravascular and it is possible to be
accompanied by biliary calculous and splenomegaly.
Nevertheless, it exists a variability in the manifestations
associated with this type of chronic anemia 47,50,51. At the
same time there are reports on cases in literature where
they describe to chronic hemolytic anemia and a cause,
although rare, is the G6PD deficiency52.
Preeclampsia . Entity apparently associated in a partial
form with a lipidic peroxidation of the plasmatic membrane
of the syncitiotrophoblast. For that reason, patients with
some alteration in the G6PD activity might have serious
difficulties in the reduction of the GSSG to GSH and thus
present alterations in the antioxidant defense53.
On the other hand, it is interesting to outline how the
G6PD deficiency (variant A-) is associated with an increase
in the resistance to the infection caused by Plasmodium
falciparum in the sub-Sahara region of Africa. This
indicates that there is a strong adaptation response in front
of this red blood cells invasion54.
CONCLUSIONS
Considering that Colombia has been seat of multiple
migrations from Africa and Europe, it is necessary to
develop surveys in order to evaluate the rank of activity of
the G6PD, as well as its possible variants in this region.
The obtained knowledge will be able to complement the
findings collected in other latitudes and therefore it will
derive in a better diagnosis, approach and treatment of the
diseases associated with the hemolysis and the oxidation,
like anemia, diabetes, arterial hypertension and cancer
among others. On the other hand, this knowledge might be
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applied in the area of the physiology of the exercise,
where, because of the oxidative stress, it could happen
from hemolysis to the sudden death of the sportsman.
Considering the increasing findings on the participation
in certain pathologies, as well as in the understanding of
evolutionary processes of the human species, the deter-
mination of the activity of this enzyme is a priority for
populations like the Colombian one where the are only
some extrapolated data obtained by WHO.
In different parts from the world different techniques
arise that intend to favor the fast determination with high
sensitivity and specificity of the activity of this enzyme55,56.
However, In Colombia only some determinations have
taken place in small groups (data without publishing), and
there exist small work groups from certain universities like
the Universidad del Rosario of Bogota’s, who will soon
give their results in relation to the prevalence of this
alteration in the metabolism of hereditary type.
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